import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: 'bpc-157-vs-tb500-stack-overnight-v2-jul1-2026',
  title: 'BPC-157 + TB-500: Research on the Combined Protocol',
  description:
    'BPC-157 and TB-500 are mechanistically complementary tissue-repair peptides. This article examines the rationale for combined protocols, what the preclinical literature shows, and quality standards for sourcing both compounds.',
  category: 'Stacks & Protocols',
  readMinutes: 11,
  publishedAt: '2026-07-01',
  ogImage: '/og-image.jpg',
  body: [
    {
      type: 'paragraph',
      text: 'BPC-157 and TB-500 (Thymosin Beta-4) are among the most studied tissue-repair peptides in the preclinical literature. While each has a substantial individual research record, researchers have increasingly examined them in combined protocols — hypothesizing that their distinct but complementary pathways may produce additive effects in tissue repair models.',
    },
    { type: 'heading', text: 'Why These Two Peptides Are Studied Together' },
    {
      type: 'paragraph',
      text: 'BPC-157 is a 15 amino acid pentadecapeptide associated with NO modulation, VEGF signaling, and FAK-paxillin activation. TB-500 is a synthetic Thymosin β4 analog that acts via G-actin sequestration and VEGF-mediated cell migration. Both show anti-inflammatory and angiogenic properties, but through distinct entry points.',
    },
    {
      type: 'table',
      headers: ['Property', 'BPC-157', 'TB-500'],
      rows: [
        ['Molecular size', '15 amino acids', '43 amino acids'],
        ['Primary mechanism', 'NO modulation, VEGF, FAK-paxillin', 'G-actin sequestration, VEGF'],
        ['Anti-inflammatory', 'Yes — systemic, via NO', 'Yes — local, via NF-κB'],
        ['Angiogenesis', 'Strong (VEGF, eNOS upregulation)', 'Moderate (secondary to cell migration)'],
        ['Cell migration', 'Indirect via signaling', 'Direct via actin cytoskeletal remodeling'],
      ],
    },
    {
      type: 'paragraph',
      text: 'The theoretical basis for combination research is simple: TB-500 may facilitate migration to the injury site via actin dynamics, while BPC-157 may promote vascularization and signaling support once those cells arrive.',
    },
    { type: 'heading', text: 'Evidence for Complementary Mechanisms' },
    {
      type: 'subheading',
      text: 'Angiogenesis',
    },
    {
      type: 'paragraph',
      text: 'Both peptides upregulate VEGF, but through different entry points. That makes the dual-pathway hypothesis mechanistically plausible, even though direct combined studies remain limited.',
    },
    {
      type: 'subheading',
      text: 'Inflammation modulation',
    },
    {
      type: 'paragraph',
      text: 'BPC-157 appears to modulate systemic inflammatory signaling, while TB-500 acts more locally at the cellular level. Together, they theoretically address both local and systemic inflammatory components of acute tissue injury.',
    },
    { type: 'heading', text: 'Preclinical Evidence and Gaps' },
    {
      type: 'paragraph',
      text: 'Direct studies of BPC-157 + TB-500 together are limited. Most available evidence comes from independent studies with overlapping models, pathway maps that show no obvious antagonism, and protocol design logic rather than head-to-head combination trials.',
    },
    {
      type: 'callout',
      text: 'The absence of direct combined studies is a real literature gap. Researchers should treat this as a hypothesis-driven area, not settled fact.',
    },
    { type: 'heading', text: 'Sourcing Both Peptides for Research' },
    {
      type: 'paragraph',
      text: 'Researchers should apply the same quality standards to both compounds: HPLC ≥99% purity with chromatogram, ESI-MS identity confirmation, LAL endotoxin testing, and cold-chain shipping. With a combined protocol, each component needs independent documentation.',
    },
    { type: 'heading', text: 'Summary' },
    {
      type: 'paragraph',
      text: 'BPC-157 and TB-500 are studied together because they map to different parts of the repair process. The combination is interesting for research design, but the direct evidence base remains thin — which is exactly why quality control and careful protocol design matter.',
    },
    { type: 'disclaimer', text: 'For research purposes only. Not intended for human use.' },
  ],
};